JP2010539155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539155A5 JP2010539155A5 JP2010524600A JP2010524600A JP2010539155A5 JP 2010539155 A5 JP2010539155 A5 JP 2010539155A5 JP 2010524600 A JP2010524600 A JP 2010524600A JP 2010524600 A JP2010524600 A JP 2010524600A JP 2010539155 A5 JP2010539155 A5 JP 2010539155A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- groups
- substituted
- halogen atoms
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 125000003277 amino group Chemical group 0.000 claims 12
- 125000002843 carboxylic acid group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000000468 ketone group Chemical group 0.000 claims 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000005841 biaryl group Chemical group 0.000 claims 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical group 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 125000006384 methylpyridyl group Chemical group 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- -1 nicotinyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- IMLPTLDALBICEO-UHFFFAOYSA-N CC(C)[n]1c(nc(cc2NCC3=CCCC=C3)[N+]([O-])=O)c2nc1 Chemical compound CC(C)[n]1c(nc(cc2NCC3=CCCC=C3)[N+]([O-])=O)c2nc1 IMLPTLDALBICEO-UHFFFAOYSA-N 0.000 description 1
- NILLRGUUQRBUFO-MRXNPFEDSA-N CC[C@H](CO)Nc(cc1NCc2ccccc2)nc2c1nc[n]2C(C)C Chemical compound CC[C@H](CO)Nc(cc1NCc2ccccc2)nc2c1nc[n]2C(C)C NILLRGUUQRBUFO-MRXNPFEDSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2007/003655 WO2009034411A1 (en) | 2007-09-12 | 2007-09-12 | Perharidines as cdk inhibitors |
| PCT/IB2008/003106 WO2009034475A2 (en) | 2007-09-12 | 2008-09-12 | Perharidines as cdk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539155A JP2010539155A (ja) | 2010-12-16 |
| JP2010539155A5 true JP2010539155A5 (enExample) | 2012-03-22 |
Family
ID=39773126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524600A Pending JP2010539155A (ja) | 2007-09-12 | 2008-09-12 | ペルハリジン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8450342B2 (enExample) |
| EP (1) | EP2185557A2 (enExample) |
| JP (1) | JP2010539155A (enExample) |
| KR (1) | KR20100075907A (enExample) |
| CN (1) | CN101809020A (enExample) |
| BR (1) | BRPI0816799A2 (enExample) |
| CA (1) | CA2699040A1 (enExample) |
| MX (1) | MX2010002477A (enExample) |
| RU (1) | RU2498984C2 (enExample) |
| WO (2) | WO2009034411A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059634A1 (en) * | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| AU2019340436B2 (en) | 2018-09-10 | 2025-04-17 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111217814B (zh) * | 2018-11-26 | 2022-08-26 | 天津科技大学 | 一类联哌啶衍生物及其作为抗肿瘤药物的应用 |
| US20230115907A1 (en) | 2019-12-20 | 2023-04-13 | Evopoint Biosciences Co., Ltd. | Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof |
| GB202108572D0 (en) * | 2021-06-16 | 2021-07-28 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN115104576A (zh) * | 2022-07-12 | 2022-09-27 | 河北医科大学 | Cdk5调控eEF2在糖尿病肾病防治中的操作方法 |
| CN118598874A (zh) * | 2024-05-21 | 2024-09-06 | 江南大学 | 一种取代的9h嘌呤类化合物、药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU566842A1 (ru) * | 1976-01-06 | 1977-07-30 | Донецкое Отделение Физико-Органической Химии Института Физической Химии Им.Л.В.Писаржевского Ан Украинской Сср | Способ получени замещенных имидазопиридинов |
| CN1377356A (zh) * | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 亚烷基二胺取代的杂环 |
| UA74593C2 (en) * | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| EP1352910A1 (en) * | 2002-04-10 | 2003-10-15 | Grünenthal GmbH | New analogs of nitrobenzylthioinosine |
| EP1538907A4 (en) * | 2002-07-02 | 2008-12-24 | Southern Res Inst | FTSZ-HEMMER AND ITS USE |
| EP1799230B1 (en) * | 2004-08-27 | 2012-11-21 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| TW200616624A (en) * | 2004-09-09 | 2006-06-01 | Solvay Pharm Bv | 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity |
| EP1824850A2 (en) * | 2004-12-09 | 2007-08-29 | Nycomed GmbH | SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION |
-
2007
- 2007-09-12 WO PCT/IB2007/003655 patent/WO2009034411A1/en not_active Ceased
-
2008
- 2008-09-12 CA CA2699040A patent/CA2699040A1/en not_active Abandoned
- 2008-09-12 EP EP08831015A patent/EP2185557A2/en not_active Withdrawn
- 2008-09-12 BR BRPI0816799-0A2A patent/BRPI0816799A2/pt not_active IP Right Cessation
- 2008-09-12 KR KR1020107007885A patent/KR20100075907A/ko not_active Withdrawn
- 2008-09-12 JP JP2010524600A patent/JP2010539155A/ja active Pending
- 2008-09-12 WO PCT/IB2008/003106 patent/WO2009034475A2/en not_active Ceased
- 2008-09-12 MX MX2010002477A patent/MX2010002477A/es active IP Right Grant
- 2008-09-12 CN CN200880106879A patent/CN101809020A/zh active Pending
- 2008-09-12 RU RU2010108507/04A patent/RU2498984C2/ru not_active IP Right Cessation
-
2010
- 2010-02-19 US US12/709,222 patent/US8450342B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539155A5 (enExample) | ||
| CN101910159B (zh) | 杂环取代吡啶衍生物的制备方法 | |
| JP2010195800A5 (enExample) | ||
| US11053188B2 (en) | Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides | |
| JP2010531876A5 (enExample) | ||
| US8450496B2 (en) | Process for the preparation of propionic acid derivatives | |
| RU2010108507A (ru) | Перхаридины в качестве ингибиторов cdk | |
| Lee et al. | Regio-and stereoselective synthesis of thiazole-containing triarylethylenes by hydroarylation of alkynes | |
| CA3065683A1 (en) | Method for producing optically active compound | |
| Zhou et al. | Synthesis of o-Alkenylated 2-Arylbenzoxazoles via Rh-Catalyzed Oxidative Olefination of 2-Arylbenzoxazoles: Scope Investigation, Structural Features, and Mechanism Studies | |
| CN105712812A (zh) | 利用不对称还原胺化反应制备的手性β-芳基胺类化合物及其方法 | |
| JP2021503470A5 (enExample) | ||
| JP2013538213A5 (enExample) | ||
| JP2010505861A5 (enExample) | ||
| Wang et al. | Pd (II)-Catalyzed Direct γ-C (sp3)-H Arylation between Free β2-Amino Esters and β3-Amino Esters and Aryl Iodides Using a Catalytic Transient Directing Group | |
| JP2016535033A5 (enExample) | ||
| US9828340B2 (en) | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide | |
| CN105209435B (zh) | 包含吡啶或吡嗪的化合物 | |
| Majoral et al. | Design, complexing and catalytic properties of phosphorus thiazoles and benzothiazoles: a concise overview | |
| JP2012524796A5 (enExample) | ||
| EP2585452B1 (en) | Process for the preparation of propionic acid derivatives | |
| CN102040564B (zh) | 一种3-胺基苯并[d]异噻唑的制备方法 | |
| JP2019522662A (ja) | ベムラフェニブの新規な製造方法 | |
| JP2006516588A5 (enExample) | ||
| JP2011525538A5 (enExample) |